Benchmark reissued their buy rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a research note published on Monday morning, Marketbeat reports. They currently have a $5.00 price objective on the medical research company’s stock, down from their previous price objective of $7.00.
Separately, HC Wainwright set a $10.00 price objective on shares of VolitionRX and gave the company a buy rating in a research report on Tuesday, February 6th.
VolitionRX opened at $2.37 on Monday, Marketbeat reports. VolitionRX has a 1-year low of $2.04 and a 1-year high of $2.21.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.